Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 500

The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.

Bone remodelling at a glance

Crockett, Julie C., Rogers, Michael J., Coxon, Fraser P., Hocking, Lynne J., Helfrich, Miep H.·2011·Journal of Cell Science

Abstract

The bone remodelling cycle (see Poster panel "The bone remodelling cycle") maintains the integrity of the skeleton through the balanced activities of its constituent cell types. These are the bone-forming osteoblast, a cell that produces the organic bone matrix and aids its mineralisation (Karsenty et al., 2009); the bone-degrading osteoclast, a unique type of exocrine cell that dissolves bone mineral and enzymatically degrades extracellular matrix (ECM) proteins (Teitelbaum, 2007); and the osteocyte, an osteoblast-derived post-mitotic cell within bone matrix that acts as a mechanosensor and an endocrine cell (Bonewald and Johnson, 2008). A fourth cell type, the bone lining cell, is thought to have a specific role in coupling bone resorption to bone formation (Everts et al., 2002), perhaps by physically defining bone remodelling compartments (Andersen et al., 2009).Molecular dissection of genetic disorders of highly increased or reduced bone mass has identified many of the crucial proteins controlling the activity of these bone cell types. This information has resulted in both novel ways to treat or diagnose more common bone disorders and a better understanding of the common genetic variants that lead to differences in bone density in the general population.In this poster article, we illustrate the crucial signalling pathways involved in bone cell differentiation, function and survival, and describe how the coupled activities of the cells in bone are maintained through intercellular interactions. We pay particular attention to the factors and signalling processes that have been found to be indispensable for the maintenance of healthy bones through the study of rare genetic diseases of bone.Osteoblast differentiation is achieved by the concerted expression of a number of key transcription factors (see Poster panel "Osteoblast lineage"), and bone formation by osteoblasts is controlled both locally and systemically during bone modelling in development (Box 1) and throughout life. Studies of diseases associated with defects in bone formation, such as developmental limb disorders and high bone mass conditions, have demonstrated the crucial importance of local bone formation control by bone morphogenetic protein (BMP) (Cao and Chen, 2005) and wingless (Wnt) (Day et al., 2005) signalling pathways for osteoblast differentiation and function. In the adult, BMP2 can act as a potent stimulator of ectopic bone formation (Chen et al., 1997) and it is used clinically to enhance bone formation, for example, during fracture repair (Govender et al., 2002). BMP signalling through the recruitment and activation of heterodimeric Smad proteins controls the expression of Runt-related transcription factor 2 (Runx2), also known as core binding factor alpha1 (cbfa1), a transcription factor indispensable for osteoblast differentiation (Ducy et al., 1997). The canonical Wnt signalling pathway is indispensable for osteoblast differentiation during skeletogenesis and continues to have important roles in mature osteoblasts (Box 2). Although the major function of circulating parathyroid hormone (PTH) is to regulate plasma calcium (see below), it also has an important role in bone formation and prevents osteoblast and osteocyte apoptosis. Intermittent administration of low levels of PTH increases osteoblast number, bone formation and bone mass, and is an established anabolic treatment for osteoporosis.The exact mechanisms involved in the anabolic effects of PTH on bone formation are not fully understood, but might involve Wnt signalling (Box 2) as well as insulin-like growth factor 1 (IGF-1). IGF-1, which is released by the liver in response to growth hormone, has a role in the commitment of mesenchymal stem cells to osteoprogenitor cells. IGF-1 also regulates osteoclastogenesis both directly, through the IGF receptor (IGFR) present on osteoclasts, and by upregulating the crucial osteoclast differentiation factor receptor activator of nuclear factor κB ligand (RANKL).Another pathway by which osteoblast function is regulated is the sympathetic nervous system (Elefteriou et al., 2005). Sympathetic stimulation through the β2 adrenergic receptor located on osteoblasts inhibits bone formation and increases bone resorption, thereby resulting in a reduction in bone mass.Osteoclasts are large, multinucleated cells that form through fusion of mononuclear precursors of the hematopoietic lineage (see Poster panel "Osteoclast lineage"). Osteoclast differentiation initially depends on signalling through c-fms, the receptor for macrophage colony stimulating factor (MCSF), in mononuclear precursor cells, which upregulates expression of RANK (Crockett et al., 2011). Its ligand, RANKL, is expressed in osteoblasts and stromal cells in response to PTH and stimulation by the active dihydroxy form of vitamin D3 (1,25 Vit D3) (Leibbrandt and Penninger, 2008). Signalling through RANK and c-fms in mononuclear precursors is the key driver of osteoclast formation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1242/jcs.063032

Cites

105 of 105 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

See all 500

Metadata

Authors
Crockett, J. C., Rogers, M. J., Coxon, F. P., Hocking, L. J., & Helfrich, M. H.
Venue
Journal of Cell Science
Published
2011-04-01
Volume
124
Issue
7
Pages
991-998
ISSN
  • 0021-9533 (ISSN-L)
  • 1477-9137
OpenAlex
W2124157902
Cited by
500
References
105
FWCI
7.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.